Antimalarial Drugs in Systemic Lupus Erythematosus: Use in Pregnancy

Miriam B. Borden and Ann L. Parke
Additional contact information
Miriam B. Borden: University of Connecticut
Ann L. Parke: University of Connecticut

Drug Safety, 2001, vol. 24, issue 14, No 4, 1055-1063

Abstract: Abstract The 4-aminoquinoline radical containing antimalarial drugs are also used in the management of various connective tissue diseases including sytemic lupus erythematosus (SLE) and rheumatoid arthritis. These agents are particularly useful for themanagement of inflammatory polyarthritis and skin disease. By raising the pH in intracellular compartments, these drugs interfere with normal phagocytic function which consequently enables themto interfere with antigen processing. Other actions include inhibition of platelet aggregation, this is advantageous in patients with phospholipid antibodies (aPL) which are known to predispose patients to recurrent arterial and venous clinical thrombotic events. Hydroxychloroquine has also been demonstrated to reduce serum lipid levels including cholesterol, triglycerides and low density lipoproteins. As it is now known that patients with SLE are at risk for accelerated artherogenesis and premature heart disease, this action may be an added benefit for these patients. The use of the 4-aminoquinoline radical containing antimalarial drugs during pregnancy is controversial. It is known that these agents can cross the placenta and are deposited in fetal pigmented tissues. These findings have led to the recommendation that these agents should be discontinued in pregnancy for patients with connective tissue diseases even though they have long been recommmended for malarial prophylaxis in pregnant women travelling to malarial infested areas. Flares of SLE disease have been documented when these agents are discontinued and as flares of SLE disease activity are known to be detrimental to pregnancy outcome in patients with SLE, it is our opinion that these drugs should not be discontinued during pregnancy in a patient with lupus, particularly when the known terminal elimination half life is 1 to 2 months.

Date: 2001
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.2165/00002018-200124140-00004 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:24:y:2001:i:14:d:10.2165_00002018-200124140-00004

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.2165/00002018-200124140-00004

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().